Table 3.

Hematologic and nonhematologic adverse events

All patients
First cohort
Second cohort
Third cohort
 %
No. per patient
 %
No. per patient
 %
No. per patient
 %
No. per patient
Hema AEs         
   Neutropenia, grade 3/4   63   1.69   54   1.37   66   1.66   68   1.99  
   Thrombocytopenia, grade 3   28   0.39   18   0.22   33   0.44   31   0.52  
   Anemia, grade 3   1   0.04   4   0.11   —   —   —   —  
Non-Hema AEs         
   Grade 2   38   1.95   52   2.18   22   1.78   35   1.84  
   Grade 3   38   0.99   22   0.59   33   1.00   55   1.32  
   Grade 4   3   0.03   —   —   11   0.11   —   —  
   Total
 		 79
 		 2.97
 		 74
 		 2.77
 		 66
 		 2.89
 		 90
 		 3.16
 
All patients
First cohort
Second cohort
Third cohort
 %
No. per patient
 %
No. per patient
 %
No. per patient
 %
No. per patient
Hema AEs         
   Neutropenia, grade 3/4   63   1.69   54   1.37   66   1.66   68   1.99  
   Thrombocytopenia, grade 3   28   0.39   18   0.22   33   0.44   31   0.52  
   Anemia, grade 3   1   0.04   4   0.11   —   —   —   —  
Non-Hema AEs         
   Grade 2   38   1.95   52   2.18   22   1.78   35   1.84  
   Grade 3   38   0.99   22   0.59   33   1.00   55   1.32  
   Grade 4   3   0.03   —   —   11   0.11   —   —  
   Total
 		 79
 		 2.97
 		 74
 		 2.77
 		 66
 		 2.89
 		 90
 		 3.16
 

The frequency of adverse events (AEs) has been calculated both as the percent of patients who suffered at least one of the adverse events (%) and as the number of AEs per patient. For all patients, n = 76; first cohort, 27; second cohort, 18; and third cohort, 31.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal